Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
US-2022315893-A1 · Oct 6, 2022 · US
US9850465B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9850465-B2 |
| Application number | US-201414770625-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2014 |
| Priority date | Feb 27, 2013 |
| Publication date | Dec 26, 2017 |
| Grant date | Dec 26, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods for generating thymic epithelial progenitor (TEP) cells from pluripotent stem (PS) cells in vitro are provided. Compositions and systems of cell populations of TEP cells as well as cells formed during different stages of differentiation of PS cells into TEP cells are also disclosed. The methods, isolated in vitro cell populations, compositions, and systems disclosed provide functional TEP cells that mature into thymic epithelial cells in vivo.
Opening claim text (preview).
What is claimed is: 1. A method for generating thymic epithelial progenitor (TEP) cells, the method comprising: culturing definitive endodermal (DE) cells, obtained from pluripotent stem cells, in a medium comprising an activator of retinoic acid receptor, an activator of bone morphogenetic protein (BMP) signaling, and an inhibitor of transforming growth factor-β (TGF-β) signaling to produce anterior foregut endodermal (AFE) cells; culturing the AFE cells in a medium comprising an activator of retinoic acid receptor, an activator of bone morphogenetic protein (BMP) signaling, and an inhibitor of transforming growth factor-β (TGF-β) signaling to produce ventral pharyngeal endodermal (VPE) cells; and culturing the VPE cells in a medium comprising an activator of retinoic acid receptor and an activator of bone morphogenetic protein (BMP) signaling to produce the TEP cells. 2. The method of claim 1 , wherein the DE cells are obtained from pluripotent stem cells by culturing pluripotent stem cells in a medium comprising a growth factor selected from the group consisting of Nodal, Activin A, and Activin B. 3. The method of claim 2 , wherein the medium for culturing the AFE cells further comprises a Wnt family member, a fibroblast growth factor (FGF), and an inhibitor of hedgehog signaling. 4. The method of claim 3 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 5. The method of claim 3 , wherein the TEP cells express FOXN1. 6. The method of claim 2 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 7. The method of claim 6 , wherein the TEP cells express FOXN1. 8. The method of claim 2 , wherein the TEP cells express FOXN1. 9. The method of claim 1 , wherein the pluripotent stem cells are selected from the group consisting of embryonic stem cell, embryonic germ cells, and induced pluripotent stem cell. 10. The method of claim 9 , wherein the pluripotent stem cells are primate pluripotent stem cells (pPS) cells. 11. The method of claim 10 , wherein the pPS cells are human pluripotent stem (hPS) cells. 12. The method of claim 11 , wherein the hPS cells are human embryonic stem (hES) cells. 13. The method of claim 11 , wherein the hPS cells are induced pluripotent stem (iPS) cells. 14. The method of claim 1 , wherein the medium for culturing the AFE cells further comprises a Wnt family member, a fibroblast growth factor (FGF), and an inhibitor of hedgehog signaling. 15. The method of claim 14 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 16. The method of claim 14 , wherein the TEP cells express FOXN1. 17. The method of claim 1 , wherein the medium for culturing the VPE cells further comprises a Wnt family member, a fibroblast growth factor, and an inhibitor of hedgehog signaling. 18. The method of claim 17 , wherein the TEP cells express FOXN1. 19. The method of claim 1 , wherein the TEP cells express FOXN1.
Wnt; Frizzeled · CPC title
Hedgehog proteins; Cyclopamine (inhibitor) · CPC title
Activin; Inhibin; Mullerian inhibiting substance · CPC title
of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] · CPC title
from embryonic cells · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.